Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer.
The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors.
The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells.
Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -0.78 Decreased by -4.00% | -0.85 Increased by +8.24% |
| May 16, 24 | -0.82 Decreased by -10.81% | -0.79 Decreased by -3.80% |
| Feb 8, 24 | -0.77 Decreased by -11.59% | -0.93 Increased by +17.20% |
| Nov 7, 23 | -0.90 Decreased by -13.92% | -0.86 Decreased by -4.65% |
| Aug 3, 23 | -0.75 Increased by +3.85% | -0.84 Increased by +10.71% |
| May 18, 23 | -0.74 Decreased by -23.33% | -0.67 Decreased by -10.45% |
| Feb 9, 23 | -0.69 Decreased by -21.05% | -0.75 Increased by +8.00% |
| Nov 3, 22 | -0.79 Decreased by -41.07% | -0.78 Decreased by -1.28% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Decreased by N/A% | -53.05 M Increased by +11.64% | - - |
| Jun 30, 24 | 0.00 Decreased by N/A% | -53.77 M Decreased by -8.51% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 4.04 M Increased by +N/A% | -55.08 M Decreased by -11.85% | Decreased by -1.36 K% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -51.12 M Decreased by -28.80% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -60.04 M Decreased by -39.31% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -49.55 M Decreased by -17.28% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -49.24 M Decreased by -55.35% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -39.69 M Decreased by -33.75% | Decreased by N/A% Decreased by N/A% |